ライフサイエンスコーパス: dyspnea

1 sources varied from 0.79 (diabetes) to 0.02 (dyspnea).

2 atients with PH-LHD or otherwise unexplained dyspnea.

3 ecome an efficient tool in the management of dyspnea.

4 pressures during exercise that contribute to dyspnea.

5 1 of 4 RFA animals (25%) developed fever and dyspnea.

6 ed urticaria and one developed urticaria and dyspnea.

7 tigue, neutropenia, alopecia, dizziness, and dyspnea.

8 uction and intermittent wheezing, cough, and dyspnea.

9 tical mechanical constraints and intolerable dyspnea.

10 associated with greater early improvement in dyspnea.

11 individuals undergoing evaluation of chronic dyspnea.

12 e syndrome including fever, hypotension, and dyspnea.

13 year smoking history presents with cough and dyspnea.

14 ock, acutely manifested with hypotension and dyspnea.

15 % of women; P = 0.59), mainly chest pain and dyspnea.

16 pper respiratory tract infection, cough, and dyspnea.

17 tients with poorly controlled disease and/or dyspnea.

18 tted to our hospital because of wheezing and dyspnea.

19 ignificantly associated with the presence of dyspnea.

20 illing pressure in patients with unexplained dyspnea.

21 od from the rectum, progressive fatigue, and dyspnea.

22 th holding of similar duration caused severe dyspnea.

23 aluated in the ED at a Mayo Clinic site with dyspnea.

24 oxygen levels incompatible with life without dyspnea.

25 erizing the burden of PH in individuals with dyspnea.

26 n, generalised muscle weakness, syncope, and dyspnea.

27 t with patient reports of moderate to severe dyspnea.

28 common cause of discontinuation followed by dyspnea.

29 lushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%).

30 y of which were anxiety (0.98% [n = 87]) and dyspnea (0.93% [n = 83]).

31 eath, and 5 hospitalizations-1 chest pain, 2 dyspnea, 1 heart failure, and 1 syncope) over 368+/-156

32 atios (95% confidence intervals) as follows: dyspnea-1.31 (1.10-1.56), 2.20 (1.81-2.68), and 10.73 (8

33 n symptoms were central chest pain (25%) and dyspnea (12%).

34 pain (15%), 53 of 387 with chest pain and/or dyspnea (14%), and 49 of 433 with headache (11%) returne

35 pain (25%), 72 of 387 with chest pain and/or dyspnea (19%), and 81 of 426 with headache (19%).

36 rhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%).

37 fection (42%), infusion reactions (42%), and dyspnea (40%).

38 ain (51%), 163 of 387 with chest pain and/or dyspnea (42%), and 103 of 433 with headache (24%).

39 symptoms were fever (70%), cough (59%), and dyspnea (43%).

40 ), productive sputum (55%), fever (63%), and dyspnea (49%).

41 Symptoms included cough (66%), dyspnea (50%), fever (47%), and gastrointestinal upset (

42 The main symptom at presentation was dyspnea (59.4%), with peripheral eosinophilia observed i

43 were anemia (10.8%), thrombocytopenia (7%), dyspnea (6.2%), and neutropenia (6.2%).

44 .5% of patients, respectively; P < .001) and dyspnea (6.5%, 4.6%, and 0.8% of patients, respectively;

45 The most common symptoms were dyspnea (67%), cough (45%), fatigue (45%), and decreased

46 Among patients with baseline dyspnea, 70% reported less dyspnea at 1 month after CTO

47 I], 1 to 12 percentage points) and help with dyspnea (78% v 70%; adjusted difference, 8 percentage po

48 t commonly reported symptoms were exertional dyspnea (78%) and fatigue (73%).

49 6%), a 1.6-fold increased odds of exertional dyspnea (95% CI = 1.3-1.9), a 1.5-fold increased odds of

50 The maximum dyspnea achieved during bronchial challenge correlated w

51 pital because of nasal drop, itchy eyes, and dyspnea after lunch every two months for 2 years.

52 pping was the main determinant for decreased dyspnea after surgery (odds ratio, 1.2; 95% confidence i

53 s with symptoms (often persistent) including dyspnea and a productive cough.

54 ical angina decreased, whereas patients with dyspnea and atypical angina increased.

55 Changes in dyspnea and chest tightness were evaluated on a visual a

56 management would be advantageous to improve dyspnea and clinical outcomes while minimizing the risks

57 dney transplant recipient who presented with dyspnea and cough and was diagnosed with COVID-19 pneumo

58 A 68 year-old woman with dyspnea and cough had been treated with inhaled corticos

59 is a clinical syndrome marked by progressive dyspnea and cough with the absence of parenchymal lung d

60 with asthma may falsely attribute exertional dyspnea and esophageal reflux to asthma, leading to exce

61 of HFpEF and one of the primary reasons for dyspnea and exercise intolerance in these patients.

62 see text]co2 in mild COPD and its impact on dyspnea and exercise intolerance.

63 ion and mastery domains) and physical score (dyspnea and fatigue domains) (P < 0.05).

64 complaining of unspecific symptoms, such as dyspnea and fatigue.

65 dry cough, persistent fever, and progressive dyspnea and hypoxia, sometimes accompanied by diarrhea a

66 alve implantation and usually presented with dyspnea and increased gradients.

67 ing surgical repair of the mitral valve, the dyspnea and palpitations resolved.

68 e who presented with progressively worsening dyspnea and palpitations.

69 All 10 patients presented with worsening dyspnea and pleural effusions.

70 We examined the prevalence of dyspnea and predictors of its improvement among patients

71 studied individuals with chronic exertional dyspnea and preserved ejection fraction who underwent ca

72 ejection fraction (HFpEF) typically develop dyspnea and pulmonary congestion upon exercise.

73 malignant pleural effusions have significant dyspnea and shortened life expectancy.

74 Moreover, maximum dyspnea and the Borg-oxygen uptake (V'O2) slope were sig

75 These mechanisms include the way dyspnea and the respiratory centers respond to low level

76 1.5%), fatigue (51.5%), pyrexia (42.4%), and dyspnea and thrombocytopenia (each 39.4%) were the most

77 and the relationship between nurse-detected dyspnea and treatment.

78 an was transferred to our emergency room for dyspnea and wheals on the entire body.

79 t, a 35-year-old woman, was homebound due to dyspnea and worsening cyanosis.

80 t Pain), patients with stable chest pain (or dyspnea) and intermediate pretest probability for obstru

81 sputum production, pleuritic chest pain, and dyspnea) and no worsening of symptoms at 72 to 120 hours

82 s, all-cause mortality, quality of life, and dyspnea); and treatment harms.

83 3-year mortality and the predictors of age, dyspnea, and airflow obstruction were available.

84 italization within the previous 36 h, active dyspnea, and any of the following: 1) estimated glomerul

85 s cause abrupt onset of nonproductive cough, dyspnea, and chills with arthralgias or malaise usually

86 Arterial blood gases, dyspnea, and comfort were recorded.

87 Vital signs, age, BMI, dyspnea, and comorbidities were the most important predi

88 In patients hospitalized with AHF, dyspnea, and congestion, the addition of tolvaptan to a

89 episodic or persistent symptoms of wheezing, dyspnea, and cough.

90 h left ventricular ejection fraction </=40%, dyspnea, and elevated plasma concentrations of natriuret

91 ), and body mass index, airflow obstruction, dyspnea, and exercise capacity index (adjusted beta = 0.

92 BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index, -1.8 points (all

93 me reduction, hyperinflation, health status, dyspnea, and exercise capacity.

94 cores, Body-mass index, airflow Obstruction, Dyspnea, and Exercise index, or Global Initiative for Ch

95 lier dynamic mechanical constraints, greater dyspnea, and exercise intolerance in mild COPD.

96 o2 and its impact on operating lung volumes, dyspnea, and exercise tolerance in these patients.

97 BODE [body mass index, airflow obstruction, dyspnea, and exercise] index, 6 [5-7]).

98 ients with abdominal pain, chest pain and/or dyspnea, and headache; P < .0001); median post-CT confid

99 dyspnea ratings relative to patient-reported dyspnea, and the relationship between nurse-detected dys

100 es after ingestion, he experienced coughing, dyspnea, and wheezing and had to be treated by anti-hist

101 ntially compatible with AF, such as fatigue, dyspnea, and/or palpitations.

102 ar outflow tract obstruction and symptoms of dyspnea, angina, and syncope.

103 However, even when detected by nurses, dyspnea appeared to be undertreated.

104 Attention to symptoms of weight gain and dyspnea are central tenets of patient education in heart

105 Palpitations and dyspnea are fundamental to the human experience of panic

106 The reasons for dyspnea are often multifactorial.

107 s caring for patients with hypoxemia free of dyspnea are operating in the dark, placing vulnerable pa

108 HF symptoms, especially exertional dyspnea, are common in ARVC/D; yet, classic left-sided s

109 ints included the clinical congestion score, dyspnea assessment, net urine output, and net weight cha

110 nts with baseline dyspnea, 70% reported less dyspnea at 1 month after CTO PCI.

111 uration were associated with more persistent dyspnea at 24 h (>1 to 12 months, odds ratio [OR]: 1.20;

112 rollment predicted higher risk of persistent dyspnea at 6 hours (per 10 patient increase: odds ratio

113 es up to 5 years after surgery, for example, dyspnea at 6 months (MD 11, 95% CI 4-19) and global QOL

114 90 days; patient-reported thoracic pain and dyspnea at 7, 30, 90, and 180 days; health-related quali

115 dpoint was a 7-point change in self-assessed dyspnea at 8 and 16 h, using a novel standardized approa

116 A total of 800 (81%) reported some dyspnea at baseline with a mean (+/-SD) Rose Dyspnea Sca

117 Congestive heart failure, paraplegia, dyspnea at rest, and reoperation are associated with the

118 tive heart failure, paraplegia, reoperation, dyspnea at rest, nongastric band surgery, age >/=60 year

119 all participants reporting palpitations and dyspnea at the 2 mug dose.

120 nation was normal, but she had complained of dyspnea at the round.

121 dysgeusia (both incidence and severity) and dyspnea (both incidence and severity) in the second pati

122 ly proven HFpEF (n=50) and participants with dyspnea but no identifiable cardiac pathology (n=24).

123 the unpleasant sensation of breathlessness (dyspnea) caused by airway obstruction.

124 eous disease, often manifesting with wheeze, dyspnea, chest tightness, and cough as prominent symptom

125 ined as no plan to restore sinus rhythm) and dyspnea classified as New York Heart Association class I

126 lated missing data by omitting the predictor dyspnea cohort-wide, and we present 6 methods for handli

127 The geographical, anthropometrics, FEV1, dyspnea, comorbidities, and health status scores were me

128 nce and relief of common symptoms (ie, pain, dyspnea), concordance with patients' wishes for EOL care

129 ential diagnosis of patients presenting with dyspnea, congestion, and a normal ejection fraction.

130 ted high rates of severe symptoms, including dyspnea, constipation, low appetite, fatigue, depression

131 with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy.Conclusions: T

132 apnea evoked by stimulation and expressed no dyspnea, despite being awake and vigilant.

133 Wheals and dyspnea developed one hour later and were successfully t

134 We sought to evaluate the perception of dyspnea during bronchial challenge and exercise testing

135 dent experienced generalized itchy wheal and dyspnea during physical exercise after lunch.

136 In patients with unexplained dyspnea, E/e' ratio neither accurately estimates PAWP no

137 toms (eg, odynophagia, dysphagia, dysphonia, dyspnea, earache, nasal obstruction) occurred in 48 (98%

138 tolvaptan to a background diuretic improved dyspnea early in patients selected for an enhanced vasop

139 ically meaningful benefits in lung function, dyspnea, exercise tolerance, and quality of life, with a

140 and fatigue; grade 3 or higher AEs included dyspnea, fatigue, and SSTD.

141 arging cervical lymphadenopathy, progressive dyspnea, fatigue, night sweats, and an unintentional wei

142 The patient denied chest pain, dyspnea, focal weakness, or prior similar episodes.

143 try included normal adjusted mean values for dyspnea grade (0.8), St. George's Respiratory Questionna

144 R, 4.80; 95% CI, 1.68-13.69; P = 0.003), MRC dyspnea grade (OR, 2.57; 95% CI, 1.44-4.59; P = 0.001),

145 ype III (PIIINP) was significantly higher in dyspnea group than in controls (p = 0.01).

146 Personal caregivers' ratings of dyspnea had substantial agreement with patient ratings (

147 Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor d

148 tory of heart disease, symptoms of angina or dyspnea, hemoglobin <12 mg/dl, vascular surgery, and eme

149 Dyspnea, hospitalization, and disease severity were sign

150 A 56-year-old man who developed hypotension, dyspnea, hypoxia, and pulseless electrical activity 10 d

151 FTR was independently associated with more dyspnea, impaired kidney function, and lower cardiac out

152 Conclusion Dyspnea improved in obese participants after weight redu

153 y noncardiac causes of dyspnea reported less dyspnea improvement after CTO PCI.

154 , and lung disease were associated with less dyspnea improvement after PCI.

155 and patients experiencing moderate or marked dyspnea improvement on day 1 were classified as early re

156 ul CTO PCI was associated with more frequent dyspnea improvement than failure, even after adjustment

157 Dyspnea improvement was defined as a >/=1 point decrease

158 Predictors of dyspnea improvement were examined with a modified Poisso

159 nous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated

160 the use of V/Q scanning in the evaluation of dyspnea in adult SCD patients given the important implic

161 ine, to induce sensations of palpitation and dyspnea in healthy individuals (n=23) during arterial sp

162 The mechanisms underlying dyspnea in interstitial lung disease (ILD) and chronic o

163 olic ejection time, and it may have improved dyspnea in the high-dose group.

164 need for improved detection and treatment of dyspnea in the MICU.

165 lling 788 patients hospitalized for AHF with dyspnea, increased plasma concentrations of natriuretic

166 atching (increased dead space) and resultant dyspnea, independent of markers of cardiac function.

167 t (SLS-I and II) using 2 anchors: Transition Dyspnea Index (>/=change of 1.5 units for improvement an

168 ose FEV1, 2-h post-dose FEV1, and Transition Dyspnea Index (TDI) focal score, all measured at week 26

169 st total score of 10 or more, and a Baseline Dyspnea Index focal score of 10 or less.

170 ory Questionnaire total score and transition dyspnea index total score and reduction in daily rescue

171 Medical Research Council scale and baseline dyspnea index), quality of life (QoL), mood disorders, e

172 a, wheezing, worsening bronchitis, worsening dyspnea, influenza, pneumonia, other respiratory infecti

173 re, helmet NIV improves oxygenation, reduces dyspnea, inspiratory effort, and simplified pressure-tim

174 entilation efficiency (VE/VCO(2) ratio), and dyspnea intensity (Borg scale) in HF and healthy subject

175 The relationship between dyspnea intensity and EMGdi/EMGdi,max during exercise wa

176 id not influence the key association between dyspnea intensity and inspiratory neural drive to the di

177 Hyperinflation contributes to dyspnea intensity in COPD.

178 Standardized dyspnea intensity ratings were also higher (P<0.05) in p

179 Rationale: Dyspnea is a common and distressing physical symptom amo

180 Dyspnea is a common angina equivalent that adversely aff

181 Dyspnea is a common symptom among patients undergoing CT

182 to the emergency department (ED) with acute dyspnea is challenging.

183 uation should be suggested when dysphonia or dyspnea is observed at the acute stage of SJS/TEN.

184 Dyspnea is the most common symptom among hospitalized pa

185 PE, 2-pillow orthopnea, paroxysmal nocturnal dyspnea, left and right ventricular structure and functi

186 When dyspnea limits activity or quality of life, COPD should

187 ncil [mMRC] scale 0 to 4; 4 represents worse dyspnea; MCID, 0.7 units), baseline 6-minute walk distan

188 16, 95% CI 5-26), pain (MD 18, 95% CI 7-30), dyspnea (MD 15, 95% CI 2-27), insomnia (MD 20, 95% CI 8-

189 of life (QOL) (MD -10, 95% CI -18 to -2) and dyspnea (MD 16, 95% CI 5-27) from 3 years onwards, compa

190 Secondary outcomes were baseline measures of dyspnea (modified Medical Research Council [mMRC] scale

191 , 44.3 pack-years), we evaluated spirometry, dyspnea (modified Medical Research Council grade, >/=2),

192 pic diseases), symptoms (chronic bronchitis, dyspnea-modified Medical Research Council scale and base

193 llow-up examination of survivors, persistent dyspnea (mostly mild) or functional limitation was repor

194 3, 4 events), pyrexia (n = 1, 2 events), and dyspnea (n = 1, 2 events).

195 r spirometry (n = 697), cough (n = 722), and dyspnea (n = 1,050).

196 common clinical presentation was exertional dyspnea (n=17; 65%), whereas 8 (31%) patients had no wor

197 consecutive patients with chronic exertional dyspnea (New York Heart Association class II to IV) and

198 NOCA subjects (n=185; 47%) had more limiting dyspnea (New York Heart Association classification III/I

199 ubjects (age 67 +/- 9 years) with exertional dyspnea (New York Heart Association functional class II

200 with stage C heart failure (HF) (exertional dyspnea, New York Heart Association functional class II

201 erval [CI], 1.30-2.12), paroxysmal nocturnal dyspnea (odds ratio 1.95; 95% CI, 1.55-2.44), and abnorm

202 he developed a nonproductive cough and mild dyspnea on exertion (Modified Medical Research Council d

203 Progressive dyspnea on exertion had developed after she returned to

204 sweats, weight loss, shortness of breath or dyspnea on exertion, or cough.

205 sented with a persistent cough and worsening dyspnea on exertion.

206 2.7% were women, and 87.7% had chest pain or dyspnea on exertion.

207 esented with a 6-week history of progressive dyspnea on exertion.

208 Dyspnea or dysphonia were significantly associated with

209 apy with LABA/LAMA in patients with COPD and dyspnea or exercise intolerance who have experienced one

210 r LAMA monotherapy in patients with COPD and dyspnea or exercise intolerance; 2) a conditional recomm

211 lure is a clinical syndrome characterized by dyspnea or exertional limitation due to impairment of ve

212 Presenting signs and symptoms included dyspnea or heart failure in 67% and atrial arrhythmias i

213 Although wheezes, dyspnea or loss of consciousness are known to occur with

214 928 of 2395 (38.8%) with available data had dyspnea or respiratory distress, and hospitalizations oc

215 es, and it did not appear to reduce residual dyspnea or RV dysfunction in these patients.

216 or CT with abdominal pain, chest pain and/or dyspnea, or headache were identified.

217 Shortness of breath, dyspnea, or respiratory distress or failure at hospital

218 Of 10 patients with dyspnea, PaHT was diagnosed in 8 and hepatopulmonary syn

219 Control and dyspnea patients had lower levels of cardiotrophin-1, cy

220 tion of fever, higher morbidity of tachypnea/dyspnea, pleural effusion, diarrhea, hepatosplenomegaly,

221 tomatic but can also result in palpitations, dyspnea, presyncope, and fatigue.

222 No independent association was found with dyspnea, QoL, exacerbations, and mortality.

223 Disease severity (dyspnea, QoL, exacerbations, comorbidities) and prognosi

224 he accuracy of nurses and personal caregiver dyspnea ratings relative to patient-reported dyspnea, an

225 At day 3, dyspnea reduction was greater with tolvaptan (p = 0.01).

226 difference in the primary endpoint of day 1 dyspnea reduction, despite significantly greater weight

227 Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4

228 Objectives: To determine the frequency of dyspnea relative to pain, the accuracy of nurses and per

229 , OM did not improve the primary endpoint of dyspnea relief (3 OM dose groups and pooled placebo: pla

230 e temporal relationship between diuresis and dyspnea relief and a possible clinical role for tolvapta

231 independently associated with greater early dyspnea relief and improved post-discharge survival comp

232 However, the association between short-term dyspnea relief and postdischarge clinical outcomes and h

233 e-specified analyses, OM resulted in greater dyspnea relief at 48 h (placebo, 37% vs. OM, 51%; p = 0.

234 Dyspnea relief by Likert scale was similar between group

235 In patients with acute heart failure (AHF), dyspnea relief is the most immediate goal.

236 Although dyspnea relief remains a goal of therapy for hospitalize

237 by discharge, whereas patient-reported early dyspnea relief was reported by 610 patients (40%).

238 with other potentially noncardiac causes of dyspnea reported less dyspnea improvement after CTO PCI.

239 6MWD), the Modified Medical Research Council Dyspnea Scale (mMRC), the COPD Assessment Test (CAT), St

240 and modified Medical Research Council (mMRC) dyspnea scale and Epworth scoring.

241 82%) were assessed for dyspnea with the Rose Dyspnea Scale at baseline and 1 month after CTO PCI.

242 was defined as a >/=1 point decrease in Rose Dyspnea Scale from baseline to 1 month.

243 dyspnea at baseline with a mean (+/-SD) Rose Dyspnea Scale of 2.8+/-1.2.

244 PF, breathlessness (Medical Research Council dyspnea scale score >1), and impaired lung function (for

245 exertion (Modified Medical Research Council dyspnea scale score of 2 [ie, he had to stop for breath

246 mptomatic (modified Medical Research Council dyspnea scale score, >=2; or COPD Assessment Test score,

247 predicted; modified Medical Research Council dyspnea scale score, 2.2 +/- 0.7; COPD Assessment Test s

248 Rose Dyspnea Scale scores range from 0 to 4 with higher score

249 -reported outcomes (Medical Research Council dyspnea scale, 5-level EuroQol 5-dimension questionnaire

250 e 12-Item Short Form Health Survey, the Rose Dyspnea Scale, the Patient Health Questionnaire-8, and t

251 1.2 to -0.2; P=0.009), and postexercise Borg dyspnea score (-2.0; 95% CI, -3.7 to -0.3; P=0.04), but

252 correlated with the Medical Research Council dyspnea score (r = 0.34; P < 0.0001), FEV1% predicted (r

253 After surgery, mMRC dyspnea score change correlated positively with air trap

254 .5 points; modified Medical Research Council dyspnea score, -0.6 points; and BODE (body mass index, a

255 Using a dyspnea score, rectal temperature, lung lesions, and vir

256 fraction (LVEF), and numerical rating scale dyspnea score.

257 Dyspnea scores during adenosine bronchial challenge and

258 echanical inspiratory constraints and higher dyspnea scores for a given work rate leading to poorer e

259 Dyspnea scores improved in both cohorts.

260 associated with improved patient comfort and dyspnea scores.

261 teroception, including a complete absence of dyspnea sensation.

262 pirometry and multiple phenotypes, including dyspnea severity (Modified Medical Research Council grad

263 l, role, and social functioning and fatigue, dyspnea, sleep, and financial problems were severely and

264 c, reported a complete lack of awareness for dyspnea, suggestive of impaired respiratory interoceptio

265 alpitations, orthopnea, paroxysmal nocturnal dyspnea, swelling of the legs or feet, abdominal pain, n

266 e nonmajor, and 86% of adverse events due to dyspnea that led to discontinuation of treatment with ti

267 everity of lung impairment, symptoms such as dyspnea, the amount of cough and sputum production, and

268 , dehydration (training: 0, control: 2), and dyspnea (training: 0, control: 2).

269 ression defined by 48-week worsening of FVC, dyspnea (University of California, San Diego Shortness o

270 hospitalized for acute heart failure and had dyspnea, vascular congestion on chest radiography, incre

271 examine whether triggering palpitations and dyspnea via stimulation of non-chemosensory interoceptiv

272 [43-138] vs. 200 [168-335]; P = 0.001), and dyspnea (visual analog scale 3 [2-5] vs. 8 [6-9]; P = 0.

273 notably of respiratory status at admission (dyspnea-Visual Analogic Scale and PaCO2 >= 45 mm Hg).

274 tongue swellings (8.7%) were associated with dyspnea, voice changes, and imminent asphyxiation.

275 Apparent subsequent differences in dyspnea warrant further exploration of the temporal rela

276 The mean prevalence of NSAID-induced dyspnea was 1.9% and was highest in the three Polish cen

277 Measurements and Main Results: Dyspnea was assessed by patients, caregivers, and nurses

278 Control Test (ACT) score <20 (n = 287), and dyspnea was defined as a modified Medical Research Counc

279 Dyspnea was limited to grade 1/2 in 10 patients.

280 Patient-reported dyspnea was measured using a 7-point Likert scale, and p

281 Physician-assessed and patient-reported dyspnea was not independently associated with HRQOL, all

282 tal physician-assessed, and patient-reported dyspnea was not independently associated with postdischa

283 wever, nurse detection of moderate to severe dyspnea was not significantly associated with any assess

284 in 97 (61%), cough was observed in 88 (56%), dyspnea was observed in 52 (33%), lymphocytopenia was ob

285 Physician-assessed dyspnea was rated as frequent or continuous in 1399 pati

286 Physician-assessed dyspnea was recorded on a daily basis from baseline unti

287 Conclusions: Dyspnea was reported at least as frequently as pain amon

288 raters, the frequency of moderate to severe dyspnea was similar or greater than that of pain (P < 0.

289 Patients with dyspnea were more likely to be female, obese, smokers, a

290 t, minor allergic symptoms of urticarial and dyspnea were observed on two occasions, but they disappe

291 Fever, respiratory symptoms, and dyspnea were the most frequent COVID-19-related symptoms

292 a, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased.

293 tive heart failure, acute renal failure, and dyspnea) were analyzed in terms of agreement between adm

294 selected patients presenting to the ED with dyspnea when analyzed with artificial intelligence and o

295 s continued to worsen, and she began to have dyspnea when she was at rest.

296 s attributable to an increased perception of dyspnea, which, during exercise, is mainly associated wi

297 led ECG to identify patients presenting with dyspnea who have left ventricular systolic dysfunction (

298 ardiography in 118 patients with unexplained dyspnea who underwent right heart catheterization.

299 om 0 to 4 with higher scores indicating more dyspnea with common activities.

300 CI (procedure success 82%) were assessed for dyspnea with the Rose Dyspnea Scale at baseline and 1 mo